These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 12627785)

  • 21. Biomimicry 1: PC.
    Cumberland DC; Gunn J; Malik N; Holt CM
    Semin Interv Cardiol; 1998; 3(3-4):149-50. PubMed ID: 10406685
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Current status of biodegradable stents.
    Tanguay JF; Zidar JP; Phillips HR; Stack RS
    Cardiol Clin; 1994 Nov; 12(4):699-713. PubMed ID: 7850839
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Synergistic effects of a novel nanoporous stent coating and tacrolimus on intima proliferation in rabbits.
    Wieneke H; Dirsch O; Sawitowski T; Gu YL; Brauer H; Dahmen U; Fischer A; Wnendt S; Erbel R
    Catheter Cardiovasc Interv; 2003 Nov; 60(3):399-407. PubMed ID: 14571494
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Polymer stent coating for prevention of neointimal hyperplasia.
    Billinger M; Buddeberg F; Hubbell JA; Elbert DL; Schaffner T; Mettler D; Windecker S; Meier B; Hess OM
    J Invasive Cardiol; 2006 Sep; 18(9):423-6; discussion 427. PubMed ID: 16954581
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term evaluation of paclitaxel-coated stents for treatment of native coronary lesions. First results of both the clinical and angiographic 18 month follow-up of TAXUS I.
    Büllesfeld L; Gerckens U; Müller R; Grube E
    Z Kardiol; 2003 Oct; 92(10):825-32. PubMed ID: 14579046
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Particle debris from a nanoporous stent coating obscures potential antiproliferative effects of tacrolimus-eluting stents in a porcine model of restenosis.
    Kollum M; Farb A; Schreiber R; Terfera K; Arab A; Geist A; Haberstroh J; Wnendt S; Virmani R; Hehrlein C
    Catheter Cardiovasc Interv; 2005 Jan; 64(1):85-90. PubMed ID: 15619311
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Drug-eluting stents: from randomized trials to the real world.
    Saia F; Degertekin M; Lemos PA; Serruys PW
    Minerva Cardioangiol; 2004 Oct; 52(5):349-63. PubMed ID: 15514571
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Safety and current indications during "real life" use of sirolimus-eluting coronary stents in Germany. Results from the prospective multicenter German Cypher Registry].
    Zahn R; Hamm CW; Zeymer U; Schneider S; Nienaber CA; Richardt G; Kelm M; Levenson B; Bonzel T; Tebbe U; Schöbel WA; Sabin G; Senges J;
    Herz; 2004 Mar; 29(2):181-6. PubMed ID: 15057439
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Coated stents: local pharmacology.
    Raman VK; Edelman ER
    Semin Interv Cardiol; 1998; 3(3-4):133-7. PubMed ID: 10406682
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Zotarolimus (ABT-578) eluting stents.
    Burke SE; Kuntz RE; Schwartz LB
    Adv Drug Deliv Rev; 2006 Jun; 58(3):437-46. PubMed ID: 16581153
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Survival of endothelial cells in vitro on Paclitaxel-loaded coronary stents.
    Prasad CK; Resmi KR; Krishnan LK; Vaishnav R
    J Biomater Appl; 2005 Apr; 19(4):271-86. PubMed ID: 15788425
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Overview of pharmacology and clinical trials program with the zotarolimus-eluting endeavor stent.
    Kandzari DE; Leon MB
    J Interv Cardiol; 2006 Oct; 19(5):405-13. PubMed ID: 17020565
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Novel paclitaxel-eluting, biodegradable polymer coated stent in the treatment of de novo coronary lesions: a prospective multicenter registry.
    Buszman P; Trznadel S; Milewski K; Rzeźniczak J; Przewłocki T; Kośmider M; Wójcik J; Janczak J; Zurakowski A; Kondys M; Król M; Kinasz L; Jaklik A; Rzeszutko Ł; Kałuza GL; Kiesz S; Gil R
    Catheter Cardiovasc Interv; 2008 Jan; 71(1):51-7. PubMed ID: 18098182
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Through the drug-eluting stent labyrinth.
    Guagliumi G; Musumeci G; Vassileva A; Tespili M; Valsecchi O
    Ital Heart J; 2003 Apr; 4(4):236-45. PubMed ID: 12784776
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The pathophysiology and burden of restenosis.
    Weintraub WS
    Am J Cardiol; 2007 Sep; 100(5A):3K-9K. PubMed ID: 17719351
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The paclitaxel-eluting stent in percutaneous coronary intervention: Part II. Comparison with the sirolimus-eluting stent, economics, and unanswered questions.
    Ray GM; Nawarskas JJ; Frishman WH
    Cardiol Rev; 2006; 14(3):143-50. PubMed ID: 16628023
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Differences of platelet adhesion and thrombus activation on amorphous silicon carbide, magnesium alloy, stainless steel, and cobalt chromium stent surfaces.
    Hansi C; Arab A; Rzany A; Ahrens I; Bode C; Hehrlein C
    Catheter Cardiovasc Interv; 2009 Mar; 73(4):488-96. PubMed ID: 19235237
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Drug-eluting stents for emerging treatment strategies in complex lesions.
    Simonton CA; Brodie BR; Wilson BH
    Rev Cardiovasc Med; 2005; 6 Suppl 1():S38-47. PubMed ID: 15665797
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Engineering aspects of stents design and their translation into clinical practice.
    Sangiorgi G; Melzi G; Agostoni P; Cola C; Clementi F; Romitelli P; Virmani R; Colombo A
    Ann Ist Super Sanita; 2007; 43(1):89-100. PubMed ID: 17536159
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Choosing a drug-eluting stent: a comparison between CYPHER and TAXUS.
    Perin EC
    Rev Cardiovasc Med; 2005; 6 Suppl 1():S13-21. PubMed ID: 15665793
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.